LOL...even with all of the insider selling, NVCR is still valued at $4.5 Billion. Please explain why you think they're going to be obsolete?
Novocure Announces LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
"The LUNAR trial is the first study in more than seven years to show a significant improvement in overall survival in metastatic non-small cell lung cancer post-platinum chemotherapy. I am heartened by this progress and the potential of this innovative therapy to help many metastatic lung cancer patients in need of new treatment choices following platinum therapy, without added systemic toxicity."
"The significant improvement in overall survival as demonstrated in the LUNAR study is groundbreaking. Lung cancer is the leading cause of cancer-related death in China, and non-small cell lung cancer is the most common form of this disease. The prognosis is often very poor for patients who progress after treatment with a platinum-containing regimen in the front-line setting," said professor Li Zhang, M.D., Sun Yat-sen University Cancer Center. "I am very excited that this novel, non-invasive device can bring significant benefit to patients living with metastatic NSCLC in China."
And while you're trying to explain why Novocure is going to be "obsolete", please explain what happened to SRPT's share price?
They actually received FDA approval for their drug...and yet, SRPT's share price has dropped from $160 to just $105 in the last 30 days!
